Global autoimmune disease diagnostics market size is anticipated to reach over US $5,054.12 million by 2026, according to the latest research available at Market Study Report, report provides extensively data on market share, growth, trends and forecasts for the period 2018-2026.
 

The human immune system basically protects the body from foreign particles such as bacteria and virus. Autoimmune diseases arise when the body’s immune system attacks one or more normally functioning healthy cells due to gene irregularities. The malfunctioning of the immune system is the outcome of the failure to identify organs, immune cells, tissues, and generating autoantibodies that target these cells.
 

Based on the findings of the report, increasing occurrence of autoimmune disease is the primary factor driving the autoimmune disease diagnostics market. According to the National Institutes of Health (NIH) 2015, autoimmune disease affected approximately 23.5 million Americans.
 

Advancements in automation technologies, rising awareness regarding health concerns, increased healthcare spending, growing federal support, and quick and easy diagnostic test results, and disease prevention are other factors driving market growth.
 

However, high-cost associated with diagnostic tests, huge turnaround time for test results, and high prevalence of false-positive outcomes are factors negatively impacting the global autoimmune diagnostics market. In addition, lack of awareness regarding various diseases and diagnostic procedures is further affecting market growth.
 

The global autoimmune disease diagnostics market is segmented based on type, end user, and geography. As per type, the market is categorized into localized autoimmune disease diagnostics and systemic autoimmune disease diagnostics.
 

Systemic autoimmune disease diagnostics is divided into systemic lupus erythematosus (SLE), ankylosing spondylitis, rheumatoid arthritis, and others. Whereas localized autoimmune disease diagnostics is segmented into Type 1 diabetes, idiopathic thrombocytopenic purpura, multiple sclerosis, hashimoto's thyroiditis, and others.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1695095/
 

Reportedly, in 2017, localized disease diagnostics led the global autoimmune disease diagnostics market. The dominance is majorly attributed to the existence of large process measurements and higher patient awareness compared to systemic diseases.
 

Based on end users, the global autoimmune disease diagnostics market is segmented into diagnostics centers, hospitals, and research laboratories.
 

Speaking of the geographical contribution, North America is anticipated to lead the global autoimmune disease diagnostics market over the forecast timeline. The dominance is primarily attributed to the increasing prevalence of common autoimmune diseases like type1 diabetes and rheumatoid arthritis. Increased funding by private and government organizations, shifting regulatory scenario, and technological advancements are driving growth in the North America autoimmune disease diagnostics market.
 

Major firms in global autoimmune disease diagnostics market include Fresenius Kabi (Fenwal), Haemonetics Corp., HemaCare Corp., Terumo BCT, Inc., Asahi Kasei Kuraray Medical Co. Ltd., B. Braun Melsungen AG, Therakos, Inc., and among others.
 

The research report also offers a brief overview of the global autoimmune disease diagnostics market with respect to Porter’s five forces, industry trends, ecosystem analysis, market forces, competitive ranking analysis, and PEST analysis. The company profiles of leading players are summarized in the report alongside their business overview, product benchmarking, financials, and recent developments.